Pathophysiology, assessment and management of multiple sclerosis spasticity: An update

Expert Review of Neurotherapeutics

Volumn 11, Issue 4 SUPPL. 1, 2011, Pages 3-8

  Haas, Judith ^a  

^a Judisches Krankenhaus Berlin   (Germany)

Author keywords

multiple sclerosis; pathophysiology; rating scales; spasticity; treatment

Indexed keywords

BACLOFEN; BENZODIAZEPINE; BOTULINUM TOXIN A; CANNABIS; CLONIDINE; DANTROLENE; GABAPENTIN; PHENOL; TIZANIDINE;

CONFERENCE PAPER; MULTIPLE SCLEROSIS; PAIN ASSESSMENT; PATIENT ASSESSMENT; RATING SCALE; SPASTICITY; WHEELCHAIR;

HUMANS; MULTIPLE SCLEROSIS; MUSCLE SPASTICITY; PLANT EXTRACTS; REPRODUCIBILITY OF RESULTS; SELF REPORT; SEVERITY OF ILLNESS INDEX;

EID: 79953834622     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.11.25     Document Type: Conference Paper

References (27)

1. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N. Engl. J. Med. 343(13), 938-952 (2000).
2. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mörk S, Bö L. Axonal transection in the lesions of multiple sclerosis. N. Engl. J. Med. 338(5), 278-285 (1998). (Pubitemid 28065253)
3. Pugliatti M, Rosati G, Carton H et al. The epidemiology of multiple sclerosis in Europe. Eur. J. Neurol. 13, 700-722 (2006). (Pubitemid 44143944)
4. Richards RG, Sampson FC, Beard SM, Tappenden P. A review of the natural history and epidemiology of multiple sclerosis: implications for resource allocation and health economic models. Health Technol. Assess. 6(10), 1-73 (2002).
5. Barnes MP, Kent RM, Semlyen JK, McMullen KM. Spasticity in multiple sclerosis. Neurorehabil. Neural Repair 17, 66-70 (2003). (Pubitemid 37102029)
6. Stevenson VL. Rehabilitation in practice: spasticity management. Clin. Rehabil. 24, 293-304 (2010).
7. Rizzo MA, Hadjimichael OC, Preiningerova J, Vollmer TL. Prevalence and treatment of spasticity reported by multiple sclerosis patients. Mult. Scler. 10(5), 589-595 (2004). (Pubitemid 39207235)
8. Hemmett L, Holmes J, Barnes M, Russell N. What drives quality of life in multiple sclerosis? QJM 97(10), 671-676 (2004). (Pubitemid 39359325)
9. Springhouse. Handbook of Signs and Symptoms (3rd Edition). Lippincott Williams & Wilkins, PA, USA (2005).
10. Hutchinson B. What is spasticity and what causes it? MS in Focus 12, 6-8 (2008).
11. Lindquist S, Bodammer N, Kaufmann J et al. Histopathology and serial, multimodal magnetic resonance imaging in a multiple sclerosis variant. Mult. Scler. 13(4), 471-482 (2007). (Pubitemid 46796507)
12. Ashworth B: Preliminary trial of carisoprodol in multiple sclerosis. Practitioner 192, 540-542 (1964).
13. Bohannon RW, Smith MB. Inter-rater reliability of a modifed Ashworth scale of muscle spasticity. Phys. Ther. 67, 206-207 (1987). (Pubitemid 17026064)
14. Farrar JT, Troxel A, Stott CG, Duncombe P. The validity, reliability and clinical importance of changes in spasticity severity measured on a 0-10 numerical rating scale. J. Neurol. 254(Suppl. 3), 21 (2007).
15. Farrar JT, Troxel AB, Stott C, Duncombe P, Jensen MP. Validity, reliability, and clinical importance of change in a 0-10 numeric rating scale measure of spasticity: a post hoc analysis of a randomized, double-blind, placebo-controlled trial. Clin. Ther. 30(5), 974-985 (2008). (Pubitemid 351799873)
16. Collin C, Davies P, Mutiboko IK et al. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. Eur. J. Neurol. 14, 290-296 (2007). (Pubitemid 46384865)
17. Hobart JC, Riazi A, Thompson AJ et al. Getting the measure of spasticity in multiple sclerosis: the Multiple Sclerosis Spasticity Scale (MSSS-88). Brain 129(Pt 1), 224-234 (2006). (Pubitemid 43063773)
18. Bavikatte G, Gaber T. Approach to spasticity in general practice. Br. J. Med. Pract. 2(3), 29-34 (2009).
19. Shakespeare D, Boggild M, Young CA. Anti-spasticity agents for multiple sclerosis. Cochrane Database Syst. Rev. 4, CD001332 (2003).
20. Beard S, Hunn A, Wight J. Treatments for spasticity and pain in multiple sclerosis: a systematic review. Health Technol. Assess. 7(40), iii, ix-x, 1-111 (2003).
21. Henze T, Rieckmann P, Toyka KV; Multiple Sclerosis Therapy Consensus Group of the German Multiple Sclerosis Society. Symptomatic treatment of multiple sclerosis. Multiple Sclerosis Therapy Consensus Group (MSTCG) of the German Multiple Sclerosis Society Eur. Neurol. 56(2), 78-105 (2006). (Pubitemid 44492163)
22. Stuke K, Flachenecker P, Zettl UK et al. Symptomatology of MS: results from the German MS Registry. J. Neurol. 256(11), 1932-1935 (2009).
23. Brichetto G, Messmer Uccelli M, Mancardi GL, Solaro C. Symptomatic medication use in multiple sclerosis. Mult. Scler. 9(5), 458-460 (2003). (Pubitemid 37287723)
24. Flachenecker P, Khil L, Bergmann S et al. Development and pilot phase of a European MS register. J. Neurol. 257(10), 1620-1627 (2010).
25. Clark AJ, Ware MA, Yazer E, Murray TJ, Lynch ME. Patterns of cannabis use among patients with multiple sclerosis. Neurology 62(11), 2098-2100 (2004). (Pubitemid 38738230)
26. Chong MS, Wolff K, Wise K, Tanton C, Winstock A, Silber E. Cannabis use in patients with multiple sclerosis. Mult Scler. 12(5), 646-651 (2006). (Pubitemid 46940639)
27. Martínez-Rodríguez JE, Munteis E, Carreño M et al. Cannabis use in Spanish patients with multiple sclerosis: fulflment of patients' expectations? J. Neurol. Sci. 273(1-2), 103-107 (2008).